AU4068602A - Combination treatment for alcoholism and alcohol dependence - Google Patents

Combination treatment for alcoholism and alcohol dependence Download PDF

Info

Publication number
AU4068602A
AU4068602A AU40686/02A AU4068602A AU4068602A AU 4068602 A AU4068602 A AU 4068602A AU 40686/02 A AU40686/02 A AU 40686/02A AU 4068602 A AU4068602 A AU 4068602A AU 4068602 A AU4068602 A AU 4068602A
Authority
AU
Australia
Prior art keywords
dichlorophenoxy
methylamine
alkyl
independently
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU40686/02A
Other languages
English (en)
Inventor
Harry Ralph Howard Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU4068602A publication Critical patent/AU4068602A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU40686/02A 2001-05-23 2002-05-16 Combination treatment for alcoholism and alcohol dependence Abandoned AU4068602A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29308801P 2001-05-23 2001-05-23
US60293088 2001-05-23

Publications (1)

Publication Number Publication Date
AU4068602A true AU4068602A (en) 2002-12-05

Family

ID=23127615

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40686/02A Abandoned AU4068602A (en) 2001-05-23 2002-05-16 Combination treatment for alcoholism and alcohol dependence

Country Status (11)

Country Link
US (2) US20030130322A1 (OSRAM)
EP (1) EP1262196A3 (OSRAM)
JP (1) JP2002370975A (OSRAM)
KR (1) KR20020090153A (OSRAM)
CN (1) CN1386503A (OSRAM)
AU (1) AU4068602A (OSRAM)
CA (1) CA2386740A1 (OSRAM)
HU (1) HUP0201722A2 (OSRAM)
NZ (1) NZ519032A (OSRAM)
PL (1) PL354110A1 (OSRAM)
ZA (1) ZA200204019B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1617832T3 (pl) * 2003-04-29 2009-01-30 Orexigen Therapeutics Inc Kompozycje wpływające na utratę wagi
US8758443B2 (en) 2005-05-06 2014-06-24 Titan Spine, Llc Implants with integration surfaces having regular repeating surface patterns
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
EP1954316A1 (en) * 2005-11-28 2008-08-13 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20090090316A (ko) 2006-11-09 2009-08-25 오렉시젠 세러퓨틱스 인크. 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
KR20190042766A (ko) 2006-11-09 2019-04-24 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
MX2009006672A (es) * 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
HRP20130621T1 (en) 2008-02-28 2013-09-30 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
NZ605709A (en) 2010-07-02 2014-08-29 Univ Virginia Patent Found Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
US20130096173A1 (en) 2011-09-09 2013-04-18 Bankole A. Johnson Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
PL3730132T3 (pl) 2012-06-06 2022-10-10 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
CN114588467B (zh) * 2022-04-01 2022-11-29 广州蓝仕威克医疗科技有限公司 一种基于气体混合比例供气解决酒精中毒的方法及呼吸机
CN115671107B (zh) * 2022-12-29 2023-04-04 文韬创新药物研究(北京)有限责任公司 用于解酒的复方药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923283B (en) * 1991-05-29 1993-01-27 Akzo Nv Phenoxyphenyl derivatives
DE69525847T2 (de) * 1994-09-19 2002-09-05 Dupont Pharmaceuticals Co., Wilmington Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
US5948807A (en) * 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
WO2000050380A1 (en) * 1999-02-23 2000-08-31 Pfizer Products Inc. Monoamine reuptake inhibitors for treatment of cns disorders
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
AU769430B2 (en) * 1999-10-13 2004-01-29 Pfizer Products Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors

Also Published As

Publication number Publication date
NZ519032A (en) 2003-10-31
HU0201722D0 (OSRAM) 2002-07-29
EP1262196A2 (en) 2002-12-04
PL354110A1 (en) 2002-12-02
HUP0201722A2 (hu) 2003-07-28
JP2002370975A (ja) 2002-12-24
US20040162316A1 (en) 2004-08-19
EP1262196A3 (en) 2002-12-18
KR20020090153A (ko) 2002-11-30
US20030130322A1 (en) 2003-07-10
CN1386503A (zh) 2002-12-25
CA2386740A1 (en) 2002-11-23
ZA200204019B (en) 2003-11-21

Similar Documents

Publication Publication Date Title
AU4068602A (en) Combination treatment for alcoholism and alcohol dependence
CA2387517C (en) Novel biaryl ether derivatives useful as monoamine reuptake inhibitors
AU783165B2 (en) Compositions and methods for treating female sexual dysfunction
US6436938B1 (en) Combination treatment for depression
TW524692B (en) 5HT1 receptor agonists and metoclopramide for the treatment of migraine
US6365598B1 (en) Pyrroloquinolines for treatment of obesity
US6410736B1 (en) Biaryl ether derivatives useful as monoamine reuptake inhibitors
TWI226829B (en) Pharmaceutical compositions for treatment of partial responders or refractory depression
TW555758B (en) Azabicyclic 5HT1 receptor ligands
ES2356446T3 (es) 5-aminometil-1h-pirrol-2-carboxilamidas sustituidas.
CN110446495B (zh) 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
JP2007529523A (ja) 肥満症を治療するためのオピオイド受容体拮抗物質としての4−(5−アミノメチル)−インドール−1−イルメチル)−ベンズアミド誘導体および関連化合物
WO2008075162A2 (en) Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction
AU4068102A (en) Combination treatment for depression and anxiety
TW589181B (en) Lymphocytic activation inhibitor and remedial agent for autoimmune disease
JP2653382B2 (ja) 3―スルホニル―3,7―ジアザビシクロ〔3,3,1〕1ナン―化合物,その製法及びこれを含有する胃の運動機能障害治療用薬剤
HK40065810A (zh) 含血清素的试剂和5-ht1a受体拮抗剂
HK1050479A (en) Combination treatment for alcoholism and alcohol dependence
MXPA00011353A (es) Uso de olanzapida en combinación con fluoxetina para terapia de la depresión refractaria
WO2004087165A1 (ja) 前立腺肥大症治療薬